Our Partnership
Key Structures
Topics
Results & Data
Impact Stories
Tanzania’s First Line of Defense Against Pandemics: Neema Vulugu
A Year in Review: 2022
Emergency HIV Prevention for People Displaced in Ukraine
Krystal’s Fight: Surviving Malaria as a Child to Combat the Disease Every Day as a Scientist
News Releases
Global Fund Praises Luxembourg’s Additional Pledge, Bringing Total Contribution …
African Leaders Unite in Pledge to End AIDS in Children
Global Fund Welcomes Singapore’s Return As a Donor
Global Fund and Private Sector Partners Launch US$50 Million Catalytic Fund to A…
Opinion
The Criminalization of Sex Work Not Only Violates Human Rights – It Adds to HIV …
A Hotline Operator’s Tireless Efforts to Keep People on Drug Treatment Despite W…
The Best Way to Prepare for the Next Pandemic Is Not What You Think
World AIDS Day: How are we supposed to protect our babies?
Updates
Featured
The Global Fund’s quality assurance information notices provide guidance and advice on how to operationalize in practical terms the consequences of a quality or a safety issue related to a product that has been procured with Global Fund funds. The initial information, stated in the notice, comes from the manufacturer of health products in question and/or is confirmed by stringent regulatory mechanisms.
Information Notices
The QA information notice 2022-01 has been withdrawn. All additional QC testing results comply with standards and therefore the potential quality issue has not been confirmed for the Artesunate powder for injection 60mg manufactured and commercialized by IPCA
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.